Losartan improved hippocampal long-term potentiation impairment induced by repeated LPS injection in rats.

Angiotensin II Type 1 Receptor Blockers / pharmacology Animals Excitatory Postsynaptic Potentials / drug effects Hippocampus / drug effects Lipopolysaccharides / administration & dosage Long-Term Potentiation / drug effects Losartan / pharmacology Male Rats Rats, Wistar
angiotensin II angiotensin II type 1 receptor blockers inflammation long-term potentiation

Journal

Physiological reports
ISSN: 2051-817X
Titre abrégé: Physiol Rep
Pays: United States
ID NLM: 101607800

Informations de publication

Date de publication:
05 2021
Historique:
revised: 19 04 2021
received: 02 01 2021
accepted: 23 04 2021
entrez: 27 5 2021
pubmed: 28 5 2021
medline: 21 1 2022
Statut: ppublish

Résumé

Cognitive impairment has been known as a common consequence of brain inflammation. Long-term potentiation (LTP), the generally accepted cellular mechanism for memory formation in the mammalian brain, has been shown to be suppressed by inflammation. Studies have shown that angiotensin II (Ang II) through the Ang II type 1 receptor (AT1R) has a role in brain and peripheral immune system communication and brain inflammation. Here, the effect of AT1R blockade on hippocampal LTP in rats undergoing repeated lipopolysaccharide (LPS) injection was investigated. Rats received intraperitoneal (ip) injections of LPS (250 μg kg

Identifiants

DOI: 10.14814/phy2.14874 PMID: 34042283 PMC: PMC8157761
pubmed: 34042283
doi: 10.14814/phy2.14874
pmc: PMC8157761
doi:

Substances chimiques

Angiotensin II Type 1 Receptor Blockers 0
Lipopolysaccharides 0
Losartan JMS50MPO89

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14874

Informations de copyright

© 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

Références

Life Sci. 2018 Jun 15;203:161-170
pubmed: 29684446
Brain Res. 1991 Oct 11;561(2):230-5
pubmed: 1802340
J Neurosci. 2010 Jun 2;30(22):7598-603
pubmed: 20519534
Exp Neurol. 2014 Nov;261:230-5
pubmed: 24837317
Pharmacol Rep. 2021 Feb;73(1):130-142
pubmed: 32696348
Adv Med. 2016;2016:7676512
pubmed: 27830176
J Neuroinflammation. 2015 Jul 16;12:133
pubmed: 26173397
Nat Rev Immunol. 2016 Jan;16(1):22-34
pubmed: 26711676
Mol Cell Neurosci. 2015 Mar;65:58-67
pubmed: 25724109
Br J Pharmacol. 2013 Jul;169(6):1404-16
pubmed: 23647130
Clin Sci (Lond). 2012 Nov;123(10):567-90
pubmed: 22827472
Neurochem Res. 2019 Jan;44(1):49-60
pubmed: 29619614
Neurosci Biobehav Rev. 2002 Aug;26(5):529-52
pubmed: 12367589
Brain. 2015 Nov;138(Pt 11):3299-315
pubmed: 26115674
Neurobiol Dis. 2013 Apr;52:229-36
pubmed: 23295855
Cytokine. 2020 Jan;125:154860
pubmed: 31574424
Front Cell Neurosci. 2015 Feb 02;9:28
pubmed: 25698933
Neuropsychopharmacology. 2008 Sep;33(10):2341-51
pubmed: 18075491
Mol Neurobiol. 2016 Dec;53(10):6950-6967
pubmed: 26666666
Cytokine Growth Factor Rev. 2017 Apr;34:27-33
pubmed: 28377062
J Neuroinflammation. 2019 Sep 13;16(1):180
pubmed: 31519175
J Neurosci. 2000 Sep 15;20(18):6811-9
pubmed: 10995825
Prog Neurobiol. 2004 Mar;72(4):263-93
pubmed: 15142685
Nature. 1993 Jan 7;361(6407):31-9
pubmed: 8421494
Neuropathol Appl Neurobiol. 2013 Feb;39(1):51-68
pubmed: 23046210
Front Mol Neurosci. 2013 Dec 04;6:46
pubmed: 24363642
J Neuroimmunol. 2003 Nov;144(1-2):61-7
pubmed: 14597099
Hypertension. 2009 Dec;54(6):1345-52
pubmed: 19805638
Life Sci. 2016 Aug 1;158:22-30
pubmed: 27341994
Brain Behav Immun. 2016 May;54:95-109
pubmed: 26774527
Iran J Basic Med Sci. 2017 Dec;20(12):1368-1376
pubmed: 29238473
Eur J Pharmacol. 2017 Apr 15;801:54-61
pubmed: 28259714
J Neuroinflammation. 2012 Feb 19;9:35
pubmed: 22339795
Mol Psychiatry. 2019 Oct;24(10):1533-1548
pubmed: 29875474
Brain Res Bull. 1998 Nov 1;47(4):311-5
pubmed: 9886781
Neuropsychopharmacology. 2011 Mar;36(4):857-70
pubmed: 21150913
Int Immunopharmacol. 2020 Sep;86:106720
pubmed: 32585605
J Cereb Blood Flow Metab. 2017 Jun;37(6):1959-1970
pubmed: 27389178
Brain Behav Immun. 2016 Feb;52:169-177
pubmed: 26520214
Psychoneuroendocrinology. 2007 Sep-Nov;32(8-10):1106-15
pubmed: 17976923
Neuroscience. 2012 Aug 2;216:133-42
pubmed: 22554776
J Neurosci. 1998 Apr 15;18(8):2974-81
pubmed: 9526014
Can J Physiol Pharmacol. 2017 Jul;95(7):850-860
pubmed: 28388365
Peptides. 1999;20(3):335-42
pubmed: 10447091
J Renin Angiotensin Aldosterone Syst. 2015 Sep;16(3):495-505
pubmed: 24622157
Brain Res. 1991 Dec 20;567(2):321-4
pubmed: 1817736
Pflugers Arch. 2013 Jan;465(1):133-51
pubmed: 22535332
Neurosci Lett. 1996 Jan 12;203(1):17-20
pubmed: 8742036

Auteurs

Mahmoud Hosseini (M)

Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Hossein Salmani (H)

Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
ORCID: 0000-0002-0643-1392

Yousef Baghcheghi (Y)

Student Research Committee, Jiroft University of Medical Sciences, Jiroft, Iran.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antagonistes des récepteurs aux angiotensines › Antagonistes du récepteur de type 1 de l'angiotensine-II › Losartan improved hippocampal long-term...
Recherchemedicale.com › Eucaryotes › Animaux › Losartan improved hippocampal long-term...
Recherchemedicale.com › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Transmission synaptique › Potentiels synaptiques › Potentiels post-synaptiques excitateurs › Losartan improved hippocampal long-term...
Recherchemedicale.com › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Hippocampe › Losartan improved hippocampal long-term...
Recherchemedicale.com › Facteurs biologiques › Toxines biologiques › Toxines bactériennes › Endotoxines › Lipopolysaccharides › Losartan improved hippocampal long-term...
Recherchemedicale.com › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Plasticité neuronale › Potentialisation à long terme › Losartan improved hippocampal long-term...
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Tétrazoles › Losartan › Losartan improved hippocampal long-term...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Losartan improved hippocampal long-term...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rat Wistar › Losartan improved hippocampal long-term...